Congressman Krishnamoorthi Responds To FDA’s Decision To Stay Its Decision To Clear the Market Of JUUL Products

SCHAUMBURG, IL – Today, Congressman Raja Krishnamoorthi who Chairs the Oversight Subcommittee on Economic and Consumer Policy and led the Congressional investigation into vaping giant JUUL Labs, Inc., issued the following statement in response to the Food and Drug Administration's (FDA) decision to "stay" its marketing denial order of all JUUL Lab Inc.'s products, which would have removed them from the market, after previously finding the company's e-cigarettes fail to meet the agency's public health standard for authorization:

"While the FDA's stay of its order against JUUL is a temporary suspension, rather than a withdrawal, I'm deeply disappointed by the FDA's continuing failure to rapidly and completely review all relevant scientific and public health research in order to take effective and conclusive action to protect our kids. The scale and damage of the youth vaping epidemic is clear and it's essential that the FDA ends its pattern of delay and missed deadlines to properly regulate the e-cigarette market."

Congressman Krishnamoorthi's statement follows the FDA's announcement of its issuing an administrative stay to "temporarily suspend the marketing denial order during the additional review but does not rescind it." While the U.S. District Court for the District of Maryland ordered the agency to begin regulating addictive, kid-friendly vaping products after years of inaction and gave the FDA a deadline of September 9, 2021, to finalize its review of e-cigarette applications, it has still failed to do so. Ten months after the deadline, after calls from Congressman Krishnamoorthi and his colleagues in the House and Senate, the FDA still has not completed its review of the products perpetuating the youth vaping epidemic.